Endocrine, metabolic & immune disorders drug targets最新文献

{"title":"Nonlinear Association Between Uric Acid to High-Density Lipoprotein Cholesterol Ratio and Diabetic Kidney Disease: Evidence from NHANES 2007-2018.","authors":"Yi Wei, Chao Liu, Jiangyi Yu","doi":"10.2174/0118715303369433250914053054","DOIUrl":"https://doi.org/10.2174/0118715303369433250914053054","url":null,"abstract":"<p><strong>Introduction: </strong>The relationship between uric acid to high-density cholesterol ratio (UHR) and diabetic kidney disease (DKD) is unclear. The aim of this study was to investigate the relationship between UHR and DKD in patients with diabetes mellitus (DM).</p><p><strong>Methods: </strong>Analyses were conducted based on National Health and Nutrition Examination Survey (NHANES) data from the 2007-2018 cycle. We used multifactorial logistic regression to analyze the association between UHR and DKD. We performed restricted cubic splines (RCS) analyses to explore whether there was a nonlinear relationship between the two. In addition, we explored differences in this association between different subgroups.</p><p><strong>Results: </strong>A total of 2,674 participants were included in the study. After adjusting for all confounding variables, multivariate logistic regression analysis revealed a significant correlation between UHR and DKD in patients with DM. RCS analysis further revealed a significant nonlinear association between UHR and DKD. Subgroup analysis showed that the association between UHR and DKD was consistent across different subgroups. In addition, the effect of UHR on DKD was significantly influenced by the level of BMI.</p><p><strong>Discussion: </strong>This study explored the relationship between UHR and DKD, contributing to a better understanding of the significance of UHR in DKD.</p><p><strong>Conclusion: </strong>Our study found a \"J\" nonlinear association between UHR and DKD in patients with DM.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic Insights into <i>Achyranthes Bidentata</i> Blume Water Extract in Alleviating NAFLD: PPARγ-Driven Synergistic Regulation of Lipid Metabolism and Macrophage Efferocytosis.","authors":"Xiong Ying Li, Ru Meng Yao, Xiao Ming Zou, Yun Xu, Sha Ying Qiu, Ping Ping He, Li Jun Wang, Shan Shan Lei","doi":"10.2174/0118715303385546250912094219","DOIUrl":"https://doi.org/10.2174/0118715303385546250912094219","url":null,"abstract":"<p><strong>Introduction: </strong>Achyranthes bidentata Blume (AB), a traditional Chinese medicine, is used to treat Non-alcoholic fatty liver disease (NAFLD), although its precise mechanism of action remains unclear. This study investigated the effects of <i>Achyranthes bidentata</i> water extract (ABW) on NAFLD in mice induced by high-fat-fed.</p><p><strong>Methods: </strong>The chemical components of Achyranthes bidentata Blume water extract (ABW) were analyzed using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). After 12 weeks of ABW treatment, liver histopathology and hepatic lipid levels, including total cholesterol (TC) and triglycerides (TG), were evaluated in NAFLD mice. Enzyme-linked immunosorbent assay, quantitative PCR, western blotting, and immunofluorescence were employed to assess changes in the PPARγ/LXRα signaling pathway and macrophage efferocytosis in vivo and in vitro.</p><p><strong>Results: </strong>In vivo, ABW treatment significantly reduced hepatic lipid accumulation (TC and TG) and alleviated hepatic lesions compared with the model group. ABW also upregulated genes associated with lipid metabolism and macrophage efferocytosis, while reducing the hepatic levels of inflammatory cytokines and the number of apoptotic cells. <i>In vitro</i>, ABW suppressed the expression of pro-inflammatory genes (<i>Il1b, Il6, Tnf, and Nos2</i>) and enhanced the expression of macrophage efferocytosis-related genes (<i>Pparγ, Gas6, Tyro3, and Axl</i>) in ox-LDL-induced Raw 264.7 cells. UHPLC-MS identified 501 compounds in ABW. Auto-docking analysis suggested that 4-dodecylbenzenesulfonic acid, isovanilic acid, and oleanolic acid are potential PPARγ activators present in ABW.</p><p><strong>Discussion: </strong>This study demonstrates that ABW ameliorates NAFLD by activating the PPARγ/LXRα signaling pathway and promoting macrophage efferocytosis.</p><p><strong>Conclusion: </strong>These findings provide a novel mechanistic insight into the therapeutic effects of multi- component herbal medicines for NAFLD.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory and Antioxidant Effects of Silibinin on Valproate-Induced Pancreatitis in Male Wistar Rats.","authors":"Mohammad Hady Khosravi, Khairollah Asadollahi, Bahareh Ghiasi, Amir Adibi, Somayeh Heidarizadi, Monireh Azizi","doi":"10.2174/0118715303411821250914094338","DOIUrl":"https://doi.org/10.2174/0118715303411821250914094338","url":null,"abstract":"<p><strong>Introduction: </strong>Valproic acid (VPA), a widely used antiepileptic drug, is associated with pancreatic toxicity. Silibinin, the active component of silymarin, exhibits antioxidant/anti-inflammatory properties. This study investigated silibinin's protective effects against VPA-induced pancreatitis.</p><p><strong>Methods: </strong>48 male Wistar rats (250-280 g) were divided into 8 groups (n=6): control, VPA-only (150,300 and 450 mg/kg), silibinin-only (150 mg/kg), and co-treatment groups. After 3 weeks, biochemical markers (amylase, lipase, SOD, CAT, TNF-α, IL-6) and histopathology (H&E staining) were analyzed. Data were compared using ANOVA/Tukey's test (p<0.05 significant).</p><p><strong>Results: </strong>VPA dose-dependently increased pancreatic enzymes and inflammatory markers, while reducing antioxidants. Silibinin co-treatment significantly attenuated these effects: Reduced amylase (642.8→375.6 U/L at 450 mg/kg VPA) and TNF-α (61.0→31.6 pg/mL) and restored SOD (10.9→18.3 U/mg) and CAT (5.3→366.2 U/mg). Histopathology confirmed reduced inflammation/ necrosis in co-treatment groups (p<0.01).</p><p><strong>Discussion: </strong>Silibinin mitigated VPA-induced pancreatitis via antioxidant (SOD/CAT upregulation) and anti-inflammatory (TNF-α/IL-6 reduction) mechanisms. The effect was dose-dependent, with optimal protection at lower VPA doses (150 and 300 mg/kg).</p><p><strong>Conclusion: </strong>Silibinin shows promise as an adjunct therapy to reduce VPA-associated pancreatic damage. Further clinical studies are warranted.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of Mercury Exposure with Serum Sex Steroid Hormones in Children 6-18 Years from NHANES 2013-2016.","authors":"Binwei Qiu, Yan Lin","doi":"10.2174/0118715303396515250912001734","DOIUrl":"https://doi.org/10.2174/0118715303396515250912001734","url":null,"abstract":"<p><strong>Introduction: </strong>To examine the relationship between mercury exposure and serum sex steroid hormones among children aged 6-18 years.</p><p><strong>Methods: </strong>Data were collected from the NHANES 2013-2016. A cohort of 2,637 Children with available information on mercury exposure, serum sex steroid hormones, and covariates was enrolled. Generalized linear models were applied to explore the association of mercury exposure with sex steroid hormones. Finally, we adopted the Bayesian kernel machine regression (BKMR) model to investigate the effect of mixture exposure to mercury on hormone levels.</p><p><strong>Results: </strong>Methyl mercury (MeHg) and total mercury (Hg) were associated with all sex steroid hormones except E2 (P <0.05). After adjusting for covariates, MeHg and Hg were related to sex hormone- binding globulin (SHBG) and free androgen index (FAI) (P <0.05). Stratified analysis by sex-puberty revealed a negative relationship between Hg and SHBG, while a positive association of MeHg with FAI in prepubertal girls (P <0.05). Their associations were confirmed by the BKMR model analysis, in which the mixture exposure was positively linked to FAI but inversely related to SHBG, particularly among prepubertal girls.</p><p><strong>Discussion: </strong>These findings suggest that mercury may disrupt sex hormone homeostasis during critical developmental windows. Appropriate measures should be implemented to mitigate the adverse effects of mercury on sex hormones in the young population. However, future longitudinal large-scale studies are required for validation.</p><p><strong>Conclusion: </strong>Exposure to MeHg and Hg is associated with increased FAI levels, but decreased levels of SHBG, which are more pronounced in girls. The heightened susceptibility of prepubertal girls underscores the need for targeted public health interventions, including dietary guidance on seafood consumption and early biomonitoring of mercury levels in high-risk populations, to mitigate potential health impacts.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145188200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the Immunomodulatory Mechanisms of Quan-du-zhong Capsule in Diabetic Kidney Disease <i>via</i> Integrated Network Pharmacology and Experimental Validation.","authors":"Guohua Liu, Chaozhong Zhou, Xunli Xiao, Siyuan Hu, Bo Xie, Zonghai Wu, Jun Xiao","doi":"10.2174/0118715303398054250823130459","DOIUrl":"https://doi.org/10.2174/0118715303398054250823130459","url":null,"abstract":"<p><strong>Introduction: </strong>Quan-du-zhong capsule (QDZ), derived from <i>Eucommia ulmoides</i> Oliv, is clinically utilized for diabetic kidney disease (DKD) management due to its renoprotective effects. Recent studies have demonstrated that QDZ ameliorates proteinuria and attenuates the decline in glomerular filtration rate (GFR) in DKD patients; however, the underlying mechanisms remain unclear.</p><p><strong>Methods: </strong>To elucidate the active components of QDZ and their potential association with immune cell modulation, we conducted bioinformatics analyses using GEO datasets and CIBERSORT to assess immune cell infiltration. Furthermore, molecular docking experiments and experimental validation were performed to verify the interactions between QDZ and potential immunotherapeutic targets.</p><p><strong>Results: </strong>Network pharmacology analysis identified the main active components of QDZ, including Quercetin, Kaempferol, β-carotene, β-sitosterol, and Syringetin. Furthermore, bioinformatics and molecular docking studies demonstrated that the FOS gene and the MAPK signaling pathway exhibit differential expression in DKD patients and were significantly correlated with immune cell activity. Notably, the active components-particularly Quercetin, Kaempferol, and Syringetin- displayed strong binding affinities to key targets. In addition, QDZ significantly upregulated FOS and MAPK expression and enhanced glucose uptake in HG-induced HEK-293 cells, suggesting its role in improving insulin sensitivity.</p><p><strong>Conclusions: </strong>This study illustrates the mechanism by which QDZ upregulates FOS expression and modulates the MAPK signaling pathway, thereby regulating immune cell function in DKD. These findings provide novel insights to inform future research and development of QDZ-based DKD therapies.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Multiomics Analysis Identifies CDO1 as a Novel Therapeutic Target for Osteoarthritis.","authors":"Zhihu Zhao, Xiangdong Wu, Duan Wang, Wei Luo, Jian-Xiong Ma, Xin-Long Ma","doi":"10.2174/0118715303387442250918111006","DOIUrl":"https://doi.org/10.2174/0118715303387442250918111006","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to identify key genes and potential therapeutic targets involved in the progression of osteoarthritis (OA) through an integrated multi-omics approach.</p><p><strong>Methods: </strong>We performed single-cell RNA sequencing (scRNA-seq) analysis on OA and control samples to define cell types and differentially expressed genes (DEGs). Bulk RNA-seq data from 7 public OA datasets were analyzed to identify DEGs, and Weighted Gene Co-expression Network Analysis (WGCNA) identified key co-expressed modules. An Integrated analysis of scRNA- seq DEGs, bulk RNA-seq DEGs, and WGCNA module genes pinpointed overlapping candidates. Functional enrichment analysis of these genes was then conducted. Mendelian randomization (MR) analysis was used to assess causal relationships between candidate genes and OA risk. The top candidate gene, CDO1, was functionally validated using siRNA-mediated knockdown in a rat OA model, assessed by histology and immunohistochemistry.</p><p><strong>Results: </strong>scRNA-seq identified 11 distinct cell types and 4,316 DEGs. Bulk RNA-seq meta-analysis revealed 3,664 DEGs, with WGCNA highlighting a key module significantly associated with OA. Integration identified 932 overlapping DEGs. Enrichment analysis implicated pathways including ferroptosis, PI3K-Akt signaling, and ECM-receptor interaction. MR analysis established CDO1 as the top causal OA risk gene (OR [95% CI] = 0.998 [0.996-0.999], P = 0.003).</p><p><strong>Discussion: </strong>In vivo, CDO1 knockdown significantly delayed OA progression in rats. Compared to controls, the si-CDO1 group showed improved cartilage structure, increased chondrocyte numbers, and enhanced type II collagen expression.</p><p><strong>Conclusion: </strong>CDO1 is a novel OA risk gene and therapeutic target. Its inhibition protects against OA progression, as supported by integrated multi-omics analysis and in vivo validation.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Exercise-Stimulated Irisin in Kidney Disease: A Systematic Review.","authors":"Enzo Shintaku, Davi Vantini, João Gabriel Bicudo Ting, Rubén David Dos Reis Zuniga, Glaucia Luciano da Veiga, Beatriz da Costa Aguiar Alves, Jéssica Freitas Encinas, Fernando Luiz Affonso Fonseca","doi":"10.2174/0118715303381483250629164853","DOIUrl":"https://doi.org/10.2174/0118715303381483250629164853","url":null,"abstract":"<p><strong>Introduction: </strong>Irisin is a hormone synthesized by skeletal muscle cells in response to physical exercise. It has been linked to various health benefits, including improved insulin sensitivity, fat burning, reduced inflammation, and potential protection against metabolic diseases, such as obesity and type 2 diabetes. This review explores the role of irisin, stimulated by physical exercise, in kidney diseases.</p><p><strong>Methods: </strong>A comprehensive review was conducted using SciELO, PubMed, Scopus, Web of Science, and EMBASE. Five articles were selected based on pre-established eligibility criteria. These studies used animal experiments, assessing irisin predominantly through Western blotting or ELISA, with aerobic exercise protocols, mainly treadmill running.</p><p><strong>Results: </strong>The results consistently showed an increase in irisin levels in response to physical exercise in animal models with kidney diseases.</p><p><strong>Discussion: </strong>Aerobic exercise increased plasma irisin expression, with better outcomes observed with low to medium-intensity training. Irisin demonstrated therapeutic potential by reducing renal cysts, inhibiting epithelial-mesenchymal transition, decreasing markers of diabetic nephropathy, and restoring autophagy in podocytes. Additionally, it activated the AMPK-Sirt1-PGC-1α pathway, suggesting antioxidant and antiapoptotic effects.</p><p><strong>Conclusion: </strong>The studies reviewed suggested that aerobic exercise increased irisin levels in animal models of kidney diseases, showing potential therapeutic effects for renal health.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric Analysis of Emerging Trends and Hotspots in the Links between Nonalcoholic Steatohepatitis and Diabetes Mellitus from 2004 to 2023.","authors":"Chen Xie, Tao Liu, Yuanxin Zhong, Zhengyu Li, Ji Xu, Zijun Zhao, Xinqiang Wang, Po Gao","doi":"10.2174/0118715303396313250904204350","DOIUrl":"https://doi.org/10.2174/0118715303396313250904204350","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;In recent years, the prevalence of nonalcoholic steatohepatitis (NASH) has been rising globally. NASH has been linked to liver fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation (LT), with the progression and severity of NASH closely impacting patients' prognosis. This increasing incidence highlights the urgent need for effective therapeutic strategies and early detection methods to mitigate the progression of the disease and improve patient prognosis. Accumulating evidence indicates that NASH and diabetes mellitus (DM) are interconnected and mutually affect each other. This study utilized bibliometric analysis to assess current publication trends and focal points in the links between NASH and DM, aiming to promote research in this area.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We thoroughly searched the Science Citation Index-Expanded (SCI-E) of the Web of Science Core Collection (WoSCC), PubMed, and the Excerpta Medica Database (Embase) to identify relevant articles on the links between NASH and DM from 2004 to 2023. The current publication trends and hotspots in this field were analyzed using the Online Analysis Platform of Literature Metrology, CiteSpace software, VOSviewer, and the R package Bibliometrix.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;From 2004 to 2023, 943 articles were found that focused on the links between NASH and DM with a noticeable surge in publications since 2015. The United States has taken the primary position in terms of the number of publications. It has also been the most active country in international collaborative efforts. The University of California, San Diego, and Kenneth Cusi were the most productive institution and scholar, respectively. The co-citation keywords cluster labels revealed 10 primary clusters: adiponectin, MAFLD, mortality, NASH, nonalcoholic fatty liver, SGLT2, neurodegeneration, LY2405319, autophagy, and hepatocytes. Recent studies focused on weight loss, fibrosis stage, NAFLD, mortality, and diabetes mellitus.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;Research on NASH and DM has transitioned from early mechanistic exploration to a current focus on weight management, diabetes control, and fibrosis prevention, particularly through lifestyle interventions and antidiabetic drug therapy. Future studies should integrate lifestyle adjustments with drug development, enhance international cooperation to fill regional research gaps, and achieve more effective management of NASH and DM.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Over the past 20 years, global publications on the relationship between NASH and DM have grown rapidly. The current research hotspots focus on weight loss, and the reduction of blood glucose and fibrosis in NASH. Maintaining a healthy diet, exercising regularly, taking appropriate medication, and being vigilant about complications are essential for delaying the progression of NASH and DM. These are also the primary future directions of research.&lt;/p&gt;&lt;p","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Anti-TPO Antibody and Inflammatory Markers with Thyroid Ultrasound Findings.","authors":"Ersin Kuloglu, Kubilay Issever, Ali Muhtaroglu, Sefer Aslan, Berkan Acar","doi":"10.2174/0118715303429924250912052941","DOIUrl":"https://doi.org/10.2174/0118715303429924250912052941","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this study was to evaluate the demographic, clinical, laboratory, and ultrasonographic characteristics of patients diagnosed with subclinical hypothyroidism, with a particular emphasis on the anti-thyroid peroxidase (anti-TPO) antibody and inflammatory biomarkers.</p><p><strong>Methods: </strong>The study included 157 patients diagnosed with subclinical hypothyroidism, categorised into anti-TPO-positive and anti-TPO-negative groups. A retrospective comprehensive evaluation comprising demographic data, thyroid medication status, ultrasonographic characteristics, and laboratory parameters was conducted and statistically analysed between the groups.</p><p><strong>Results: </strong>Of 157 patients, 48.4% were anti-TPO positive. This group was significantly associated with increased levothyroxine (LT4) use and sonographic parenchymal heterogeneity. However, there were no significant differences in nodule presence, number, size, or structure. A positive correlation was found between anti-TPO and ferritin levels. In addition, a positive correlation was observed between the thyroid-stimulating hormone (TSH)/free T4 ratio and the solidity of nodules, as well as between TSH and the neutrophil-to-lymphocyte ratio (NLR). Surprisingly, a negative correlation was found between anti-TPO levels and the number of nodules, as well as the cystic characterisation of the nodules.</p><p><strong>Discussion: </strong>In our study, higher levels of anti-TPO and TSH were associated with inflammatory markers such as ferritin and NLR, suggesting a possible link with systemic inflammation. Furthermore, anti-TPO and the TSH/T4 ratio also showed associations with specific sonographic features of the thyroid gland.</p><p><strong>Conclusion: </strong>TSH and anti-TPO levels might be associated with systemic inflammation and thyroid sonographic findings in patients with subclinical hypothyroidism.More studies on larger patient populations should confirm the same results to suggest their clinical significance.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis Revealed Circulating Methylation of <i>PDGFRB</i> Highly Related with Rheumatoid Arthritis Related Diseases.","authors":"Yu Shan, Mengru Guo, Jia Liu, Lei Wang, Yi Shen, Jianan Zhao, Kai Wei, Ping Jiang, Yiming Shi, Cen Chang, Yixin Zheng, Fuyu Zhao, Yunshen Li, Mi Zhou, Chengzhen Li, Shicheng Guo, Chao Liang, Huanru Qu, Dongyi He","doi":"10.2174/0118715303377879250831134649","DOIUrl":"https://doi.org/10.2174/0118715303377879250831134649","url":null,"abstract":"<p><strong>Introduction: </strong>To investigate the DNA methylation levels of platelet-derived growth factor receptor- B [PDGFRB] cg25613180 across rheumatoid arthritis [RA] and various further rheumatic disorders, including ankylosing spondylitis [AS], psoriatic arthritis [PsA], gouty arthritis, systemic lupus erythematosus [SLE], sjögren's syndrome [SS], and dermatomyositis [DM], using targeted DNA methylation sequencing.</p><p><strong>Methods: </strong>Methylation levels at PDGFRB cg25613180 were assessed in a cohort comprising RA patients, healthy controls [HC], and individuals diagnosed with AS, PsA, gout, SLE, SS, and DM. Pearson- 's correlation analysis was conducted to explore the relationship between PDGFRB cg25613180 methylation levels and key clinical indices associated with RA. Additionally, both univariate and multivariate logistic regression analyses were performed to evaluate the potential of methylation status as a diagnostic biomarker for RA.</p><p><strong>Results: </strong>Patients with RA demonstrated notably lower PDGFRB cg25613180 methylation levels than the HCs, with similar trends noted in the SLE and DM teams. Methylation levels are negatively correlated with inflammatory indicators like C-reactive protein [CRP], along with erythrocyte sedimentation rate [ESR] in RA. Differences in haplotype methylation were also significant between the RA and other groups, particularly for the CCCC and TCCC haplotypes. The logistic regression model provided high discriminative accuracy between RA and other conditions, particularly AS.</p><p><strong>Discussion: </strong>The results indicate that PDGFRB methylation, particularly at cg25613180, exhibits distinct patterns in RA compared to other rheumatic diseases. This suggests its potential as a diagnostic biomarker for RA. The negative correlation with inflammatory markers suggests a role for PDGFRB methylation in the inflammatory processes underlying RA. The study also highlights the utility of haplotype- specific methylation analysis in enhancing diagnostic accuracy.</p><p><strong>Conclusion: </strong>This study identifies distinct PDGFRB methylation patterns in RA, supporting its potential as a biomarker for diagnosis and differentiation from other rheumatic diseases. The findings open avenues for further exploration of PDGFRB methylation in understanding the epigenetic landscape of autoimmune rheumatic diseases and their potential for clinical applications.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}